Psilocybe mushrooms, psilocybin & psilocin



Jump to:

Page 3

Vollenweider et al. (1999). 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—A PET study with [¹¹C]raclopride. Neuropsychopharmacology.

Westberg & Karlson-Stiber (1999). [Hallucinogenic mushrooms popular again--sale via Internet]. Lakartidningen.

Lee, Cole & Linacre (2000). Identification of members of the genera Panaeolus and Psilocybe by a DNA test. A preliminary test for hallucinogenic fungi. Forensic Science International.

Sticht & Käferstein (2000). Detection of psilocin in body fluids. Forensic Science International.

Grieshaber, Moore & Levine (2001). The detection of psilocin in human urine. Journal of Forensic Sciences.

Moldavan et al. (2001). The effect of Psilocybe cubensis extract on hippocampal neurons in vitro. Fiziolohichnyi Zhurnal.

Albers et al. (2002). Synthesis of a psilocin hapten and a protein-hapten conjugate. The Journal of Pharmacy and Pharmacology.

Gouzoulis-Mayfrank et al. (2002). Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology.

Hasler et al. (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. The Journal of Pharmaceutical and Biomedical Analysis.

Passie et al. (2002). The pharmacology of psilocybin. Addiction Biology.

Kamata et al. (2003). Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. Journal of Chromatography.

Maruyama et al. (2003). [Discrimination of psychoactive fungi (commonly called "magic mushrooms") based on the DNA sequence of the internal transcribed spacer region]. Shokuhin Eiseigaku Zasshi.

Shirota, Hakamata & Goda (2003). Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom". Journal of Natural Products.

Stríbrný, Borovicka & Sokol (2003). [Levels of psilocybin and psilocin in various types of mushrooms]. Soudni Lekarstvi.

Tsujikawa et al. (2003). Morphological and chemical analysis of magic mushrooms in Japan. Forensic Science International.

Umbricht et al. (2003). Effects of the 5-HT 2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: Implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology.

Albers et al. (2004). Development of a psilocin immunoassay for serum and blood samples. International Journal of Legal Medicine.

Beuhler, Lee & Gerkin (2004). The Meixner test in the detection of alpha-amanitin and false-positive reactions caused by psilocin and 5-substituted tryptamines. Annals of Emergency Medicine.

Carter et al. (2004). Psilocybin impairs high-level but not low-level motion perception. NeuroReport.

Hasler et al. (2004). Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology.

Nugent & Saville (2004). Forensic analysis of hallucinogenic fungi: a DNA-based approach. Forensic Science International.

Anastos et al. (2005). Determination of psilocin and psilocybin using flow injection analysis with acidic potassium permanganate and tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence detection respectively. Talanta.

Bickel et al. (2005). Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse. European Journal of Emergency Medicine.

Carter et al. (2005). Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-ht 2a and 5-ht 1a agonist psilocybin. Neuropsychopharmacology.

Carter et al. (2005). Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. Journal of Cognitive Neuroscience.

Espiard et al. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: A case study. European Psychiatry.

Kamata et al. (2005). Liquid chromatography-mass spectrometric and liquid chromatography-tandem mass spectrometric determination of hallucinogenic indoles psilocin and psilocybin in "magic mushroom" samples. Journal of Forensic Sciences.

Reingardiene et al. (2005). [Hallucinogenic mushrooms]. Medicina.

Saito et al. (2005). Determination of psilocybin in hallucinogenic mushrooms by reversed-phase liquid chromatography with fluorescence detection. Talanta.

Sard et al. (2005). SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorganic & Medicinal Chemistry Letters.

Satora, Goszcz & Ciszowski (2005). Poisonings resulting from the ingestion of magic mushrooms in Kraków. Przeglad Lekarski.

Anastos et al. (2006). Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography. Science & Justice.

Anastos et al. (2006). The determination of psilocin and psilocybin in hallucinogenic mushrooms by HPLC utilizing a dual reagent acidic potassium permanganate and tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence detection system. Journal of Forensic Sciences.

Griffiths et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology.

Jensen, Gartz & Laatsch (2006). Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens. Planta Medica.

Maruyama et al. (2006). Phylogenetic relationship of psychoactive fungi based on rRNA gene for a large subunit and their identification using the TaqMan assay (II). Forensic Science International.

Moreno et al. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry.

Sempere et al. (2006). [Chronic cluster headache: Response to psilocybin]. Revista de Neurologia.

Sewell, Halpern & Pope (2006). Response of cluster headache to psilocybin and LSD. Neurology.

Attema-de Jonge et al. (2007). [Automutilation after consumption of hallucinogenic mushrooms]. Nederlands tijdschrift voor geneeskunde.

Carter et al. (2007). Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology.

Vollenweider et al. (2007). The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology.

Winter et al. (2007). Psilocybin-induced stimulus control in the rat. Pharmacology, Biochemistry and Behavior.

Wittmann et al. (2007). Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology.

Griffiths et al. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology.

McClintock, Watts & Melanson (2008). Unrecognized magic mushroom abuse in a 28-year-old man. The American Journal of Emergency Medicine.

Richards (2008). The phenomenology and potential religious import of states of consciousness facilitated by psilocybin. Archive for the Psychology of Religions.

Wackermann et al. (2008). Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters.

Barbee et al. (2009). Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006. Journal of Medical Toxicology.

Kovacic (2009). Unifying electron transfer mechanism for psilocybin and psilocin. Medical Hypotheses.

Lott, Marlowe & Forman (2009). Availability of websites offering to sell psilocybin spores and psilocybin. Journal of Psychoactive Drugs.

Matsushima et al. (2009). Effects of Psilocybe argentipes on marble-burying behavior in mice. Bioscience, Biotechnology, and Biochemistry.

Riley, Thompson & Griffin (2010). Turn on, tune in, but don't drop out: The impact of neo-liberalism on magic mushroom users' (in)ability to imagine collectivist social worlds. The International Journal on Drug Policy.